Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6719 in Advanced/Metastatic Solid Tumors With MTAP Deficiency
NCT06922357Phase 2Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ASP8731 in solid tumor, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Dose Limited Toxicity at 21 days, Maximum Tolerable Dose at 21 days and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
ASP8731
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06922357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922357.